BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9551690)

  • 1. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
    Graziadei I; Kelly T; Schirmer M; Geisen FH; Vogel W; Konwalinka G
    J Hepatol; 1998 Mar; 28(3):504-9. PubMed ID: 9551690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.
    Lech-Marańda E; Korycka A; Robak T
    Eur J Haematol; 2000 Nov; 65(5):317-21. PubMed ID: 11092462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
    Marañda E; Szmigielska A; Robak T
    Cancer Invest; 1999; 17(2):95-101. PubMed ID: 10071592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis using 2',2' difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells.
    Chow KU; Ries J; Weidmann E; Pourebrahim F; Napieralski S; Stieler M; Boehrer S; Rummel MJ; Stein J; Hoelzer D; Mitrou PS
    Ann Hematol; 2000 Sep; 79(9):485-92. PubMed ID: 11043419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
    Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
    J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar changes were induced by Cladribine and by gemcitabine, in the deoxypyrimidine salvage, during short-term treatments.
    Csapó Z; Keszler G; Sasvári-Székely M; Smid K; Noordhuis P; Peters GJ; Staub M
    Adv Exp Med Biol; 1998; 431():525-9. PubMed ID: 9598122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
    Csoka K; Liliemark J; Larsson R; Nygren P
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):47-53. PubMed ID: 7481845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia.
    Schirmer M; Geisen F; Tiefenthaler M; Konwalinka G
    Leuk Res; 1999 Dec; 23(12):1121-6. PubMed ID: 10613357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
    Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
    Naguib YW; Lansakara-P D; Lashinger LM; Rodriguez BL; Valdes S; Niu M; Aldayel AM; Peng L; Hursting SD; Cui Z
    Neoplasia; 2016 Jan; 18(1):33-48. PubMed ID: 26806350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of cytidine deaminase on antitumor activity of 2'-deoxycytidine analogs in vitro and in vivo.
    Yoshida T; Endo Y; Obata T; Kosugi Y; Sakamoto K; Sasaki T
    Drug Metab Dispos; 2010 Oct; 38(10):1814-9. PubMed ID: 20587622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-
    Sun Y; Wang J; Hao K
    Molecules; 2020 May; 25(9):. PubMed ID: 32397338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
    Gruber J; Geisen F; Sgonc R; Egle A; Villunger A; Boeck G; Konwalinka G; Greil R
    Stem Cells; 1996 May; 14(3):351-62. PubMed ID: 8724701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
    Beauséjour CM; Gagnon J; Primeau M; Momparler RL
    Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
    Bouffard DY; Momparler LF; Momparler RL
    Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
    Ross DD; Cuddy DP
    Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
    Bhalla K; Holladay C; Lutzky J; Ibrado AM; Bullock G; Jasiok M; Singh S
    Gynecol Oncol; 1992 Apr; 45(1):32-9. PubMed ID: 1601333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.